Cambridge Theranostics Ltd Report issue

For profit Phase 3
Founded: Cambridge United Kingdom (2001)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2009
NCT00939237
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

prolycopene (2 trials)

Drugs in Other Trials (1)

lycopene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aneurysm (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Heart Diseases (Phase 3)

Hemorrhage (Phase 2)

Myocardial Ischemia (Phase 3)

Subarachnoid Hemorrhage (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2